An interventional study of Early biomarker-based cardiological assessment in Heart Failure and Tachypnea, sponsored by University Hospital, Akershus. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by University Hospital, Akershus · Not applicable, Interventional, and Prevention
Patients hospitalized with tachypnea, defined as respiratory rate ≥20/ min, have substantial mortality and may suffer from different conditions, including acute heart failure (HF). Symptoms of HF can be difficult to identify and \~15% of patients with HF will not be correctly diagnosed by the treating physician in the Emergency Department. Biomarkers like B-type natriuretic peptides and cardiac troponins improve diagnostic accuracy and risk stratification. Whether early, structured biomarker assessment and structured feedback in the patient's electronic health records improve management and outcomes among unselected patients with tachypnea have previously not been explored in a randomized controlled trial.
The main research question of the study is to determine whether early structured biomarker assessment in unselected patients with tachypnea extends the time to the first event for either (1) all-cause readmission or (2) all-cause mortality; i.e. time to the combined endpoint, compared to the current strategy/standard care
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's enrollment of 574 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
Other: Early biomarker-based cardiological assessment
Routine standard of care according to the treating physician
We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
Composite of all-cause hospital readmission or all-cause mortality
Composite of all-cause hospital readmission or all-cause mortality after discharge from index hospitalization
Time frame: 12 months after discharge from index hospitalization
Hospital length of stay
Hospital length of stay during the index hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Length of stay in Intensive Care Unit/Medical Intensive Care Unit/Cardiac Intensive Care Unit
Length of stay in Intensive Care Unit/Medical Intensive Care Unit/Cardiac Intensive Care Unit during the index hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
30-day all-cause readmission
30-day all-cause readmission after discharge from index hospitalization
Time frame: 30-days after discharge from index hospitalization
Time to all-cause readmission
Time to first all-cause readmission after discharge from index hospitalization
Time frame: 12 months after discharge from index hospitalization
Number of all-cause readmission
Number of all-cause readmissions after discharge from index hospitalization
Time frame: 12 months after discharge from index hospitalization
All-cause mortality
Time to all-cause mortality after discharge from index hospitalization
Time frame: 12 months after discharge from index hospitalization
Total cost of hospitalization
Total cost of hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
All-cause mortality
All-cause mortality during the index hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Difference in cardiac biomarker concentrations during index hospitalization
Difference in the cardiac troponin T and/or I and B-type natriuretic peptide and/or N-terminal pro-B-type natriuretic peptide concentrations from hospital admission to discharge
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Difference in guideline-defined medical therapy for heart failure
Difference in guideline-defined medical therapy for heart failure, as defined by international guidelines, at discharge after index hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Cost-utility
Cost-utility for the intervention strategy
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing primary and secondary outcomes with patients stratified by concentrations of NT-proBNP measured at admission
We will assess all the primary and secondary outcomes of the study in patients stratified according to concentrations of NT-proBNP (\< 300 ng/L, 300-449ng/L, 450-899ng/L, 900-1799ng/L, \>1799ng/L) measured at admission of the index hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing primary and secondary outcomes with patients stratified by concentrations of cardiac troponin T measured at admission
We will assess all the primary and secondary outcomes of the study in patients stratified according to concentrations of cardiac troponin T (\<10ng/L, 10-89ng/L), \>89ng/L) measured at admission of the index hospitalization
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing accuracy for HF2FPEF score assessed during index hospitalization for diagnosing heart failure with preserved ejection fraction
Using c-statistics, we will assess the diagnostic accuracy of the H2FPEF score assessed during index hospitalization to predict heart failure with preserved ejection fraction in the total cohort of study patients
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing accuracy for HFA-PEFF score for diagnosing heart failure with preserved ejection fraction
Using c-statistics, we will assess the diagnostic accuracy of the HFA-PEFF score assessed during index hospitalization to predict heart failure with preserved ejection fraction in the total cohort of study patients
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing accuracy for NT-proBNP measured at hospital admission for diagnosing heart failure with preserved ejection fraction
Using c-statistics, we will assess the diagnostic accuracy of continuous concentrations of NT-proBNP measured at hospital admission to predict heart failure with preserved ejection fraction in the total cohort of study patients
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing accuracy for cardiac troponin T measured at hospital admission for diagnosing heart failure with preserved ejection fraction
Using c-statistics, we will assess the diagnostic accuracy of continuous concentrations of cardiac troponin T measured at hospital admission to predict heart failure with preserved ejection fraction in the total cohort of study patients
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing primary and secondary outcomes in the subgroup of patients classified as hospitalized due to heart failure
We will assess all the primary and secondary outcomes of the study in the subgroup of patients with heart failure as the adjudicated cause of tachypnea.
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
Assessing primary and secondary outcomes in the subgroups of patients with heart failure with reduced ejection fraction, heart failure with mildly reduced ejection, and heart failure with preserved ejection fraction
We will assess all the primary and secondary outcomes of the study in the subgroups of patients with heart failure with reduced ejection fraction, heart failure with mildly reduced ejection, and heart failure with preserved ejection fraction as the adjudicated cause of tachypnea.
Time frame: From admission to discharge of index hospitalization, assessed up to 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Mar 2025, 24 months.
Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 24 months is below that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Akershus →